Documento Tecnico di Indirizzo per Ridurre il Carico di Malattia del Cancro

Objectives

Italy’s 2011–2013 National Oncology Plan provides a comprehensive cancer-control framework spanning primary, secondary and tertiary prevention; epidemiological surveillance; timely diagnosis; integrated treatment; rehabilitation; palliative and pain care; research; technological innovation; workforce development; and public communication. Its overarching aims are to reduce cancer mortality, narrow regional disparities in access and outcomes, reduce avoidable health migration, and ensure equitable, patient-centred and sustainable care across the national territory.[1][2][3][4]

• Reduce exposure to major cancer risks through intersectoral action on tobacco, unhealthy diet, physical inactivity, harmful alcohol use, oncogenic infections, occupational hazards and environmental contaminants.[5][6][7][8]
• Expand organised, invitation-based screening for breast, cervical and colorectal cancer, improve programme quality and coverage, and evaluate innovative technologies and managed approaches to early diagnosis.[9][10][11][12]
• Strengthen cancer registries, mortality data and health-information systems to measure incidence, survival, prevalence, service pathways and regional inequalities.[13][14][15][2]
• Provide integrated diagnostic, therapeutic, follow-up, rehabilitation and supportive-care pathways that address patients’ physical, psychological, social and family needs throughout the disease trajectory.[3][16][17][18]
• Improve access to specialist services for older people, children and adolescents, patients with rare tumours, and people with onco-haematological diseases.[19][20][21][22][23]
• Modernise diagnostic imaging, pathology, endoscopy, surgery, radiotherapy, molecular diagnostics, biobanks and cellular therapies while promoting evidence-based, cost-effective and appropriate use of innovation.[24][25][26][27][28][29]
• Advance clinical and translational research, personalised molecular medicine, public health genomics and access to innovative medicines through appropriate patient selection and evidence generation.[30][31][32][33]
• Develop oncology training and communication that support informed decisions, prevention, screening participation, humane care and protection against unvalidated therapeutic claims.[34][35][36][37]

Implementation

Implementation is based on coordinated national, regional and local action through oncology networks that link centres of excellence, hospitals, community services, general practitioners, paediatricians, rehabilitation, palliative care, voluntary organisations and patient associations. The model combines central standards and information systems with regionally organised delivery, concentrating highly complex procedures in specialised centres while strengthening local access, continuity of care and home-based support.[38][17][39][4]

• Organise Regional Oncology Networks using Hub and Spoke arrangements, multidisciplinary disease-specific groups, shared guidelines, electronic clinical records, integrated pathways and defined regional coordination functions for clinical governance and activity monitoring.[2][40][39][41]
• Integrate primary care, hospital and territorial services so that general practitioners and paediatricians support prevention, suspected-cancer referral, shared treatment decisions, follow-up, symptom management, home care and end-of-life care.[16][42][19]
• Concentrate complex low-volume diagnostics, surgery, transplantation, advanced radiotherapy and rare-cancer care in accredited or designated specialist centres, supported by referral networks and quality requirements.[22][43][44][45][46]
• Use population registries, death certification, regional mortality registers, the New Health Information System and the Electronic Health Record to support surveillance, pathway analysis and service planning.[14][15][2]
• Apply quality improvement and performance assessment through screening indicators, facility benchmarking, equipment censuses, clinical audits, accreditation, treatment registries and outcome measures covering structure, process, outcomes, efficiency and patient satisfaction.[10][38][17][47][48]
• Support screening delivery through the Ministry of Health, the National Centre for Disease Prevention and Control, Regions, healthcare professionals, scientific societies and voluntary oncology organisations, with routine reporting by the National Screening Observatory.[9][49]
• Coordinate prevention beyond the health sector with education, food production, transport, urban planning, workplaces, industry, civil society and social partners, using national and regional prevention programmes.[6][50][51]
• Develop research infrastructure through multicentre clinical-study networks, biobanks, shared protocols, ethics-committee reform, electronic trial submission and collaboration among universities, Scientific Hospitalisation and Care Institutes, health services, regulators and industry.[52][32][53][54]
• Manage pharmaceutical innovation through monitoring registers, predictive biomarkers, post-marketing evidence, cost negotiation and risk-sharing or payment-by-results arrangements where treatment effectiveness is initially uncertain.[55][33][56]
• Fund selected measures through existing regional-health-fund conditions, screening-infrastructure legislation and targeted support mechanisms, but the source does not specify an overall plan budget, comprehensive financing framework or quantified funding gap.[9][12][57]

Monitoring & Evaluation

The plan combines population surveillance, service monitoring, quality assurance and evaluation across prevention, screening, treatment, rehabilitation, research and communication. Core information sources include cancer registries, mortality records, health-information systems, clinical registers, service censuses and regional or national networks.[13][14][15][4]

• Strengthen cancer registries to measure incidence, mortality, survival and prevalence; support needs assessment, prevention planning, evaluation of screening and treatment, and health-service and expenditure planning.[13]
• Improve mortality surveillance through National Institute of Statistics death-certificate collection, coding and quality checks, while regional mortality registers provide more timely local data and support screening-outcome monitoring.[14][15]
• Expand cancer-registry coverage and telematic networking, alongside the New Health Information System and Electronic Health Record, to analyse service access and diagnostic and therapeutic pathways.[15][2]
• Monitor organised breast, cervical and colorectal screening through target-population coverage, invitations, participation, detected lesions and quality indicators. The National Screening Observatory publishes regional programme progress, while the essential-level-of-care mechanism uses the proportion of the target population screened as a first-level indicator.[9][49][10]
• Evaluate screening innovations through pilot studies assessing effectiveness, organisational impact and cost-effectiveness, and apply continuous quality improvement across screening pathways.[58][11][12]
• Use environmental and occupational surveillance to map risks, monitor air pollution, asbestos, radon, food contaminants and workplace carcinogens, and guide remediation and health protection.[59][7][60]
• Assess oncology networks and specialist centres through indicators covering structure, process, quality, outcomes, efficiency, patient satisfaction, research and training; regional coordination is expected to monitor care activity and shared cancer plans.[38][39]
• Apply clinical monitoring across care pathways, including treatment adherence, adverse effects, pain, recurrence, psychosocial distress, follow-up compliance and waiting times.[16][61][18][62]
• Use accreditation, audits and registries to assure quality in paediatric oncology, transplantation, cellular therapy, surgery, pathology and advanced technology. Transplant centres are subject to activity thresholds and accreditation requirements, while surgical registries and audits are proposed to assess outcomes and variation.[63][64][48][46]
• Monitor technology availability, distribution, equipment age and utilisation through national censuses of radiology, nuclear medicine, radiotherapy and diagnostic equipment, although several extracts identify incomplete coverage and provisional data.[65][66][67][27]
• Strengthen monitoring of innovative medicines through the Oncology Medicines Monitoring Register, which provides daily updated treatment information and feedback to Regions, oncology departments, pharmacies and hospitals.[33]
• Track clinical research through the National Observatory on Clinical Trials of Medicines, including studies by phase, promoter, participating structure and region; post-marketing research is intended to assess real-world effectiveness and safety.[32][55]
• Evaluate training against pre-defined outcome indicators and assess communication through audience reach, partner participation, message exposure, expenditure against budget limits and behavioural effects.[68][69]

Many sections specify monitoring functions but do not provide a consolidated national indicator set, common reporting timetable, formal sanctions or a comprehensive accountability framework.[10][39][45][33]

Costing & Financing

Financing is principally framed through economic sustainability, efficient resource allocation, technology assessment, targeted funding and cost-effectiveness, rather than through a single costed national budget. Numerous programme areas identify investment needs but do not specify total allocations, funding gaps or financing sources.[2][58][45][4]

• Support regional screening infrastructure through funding under Law 138/04 and Law 286/06, alongside inclusion of organised breast, cervical and colorectal screening in the Essential Levels of Care.[9]
• Use cost-effectiveness and sustainability assessments to guide screening redesign, new technologies, individual prevention and the adoption of innovative population-screening methods.[10][58][11]
• Address reported inefficiency in hospital care for older people: inappropriate inpatient stays or care deliverable in day hospital or community settings were associated with incongruous expenditure of 11 billion Euro.[20]
• Recognise palliative-care financing reported for 2008, including total state financing of 86 and other financing of 40 for residential palliative-care structures, although the source does not specify currency.[70]
• Develop stable financing and remuneration for rare-tumour networks, complex procedures, histopathology review and collaborative clinical work; possible regional co-financing and Italian Medicines Agency support for independent research are also identified.[22][71][72]
• Allocate resources rationally for high-cost onco-haematology medicines, centralised complex diagnostics and technological renewal, including possible pharmaceutical-company provision of innovative medicines free of charge in controlled studies.[73][74][24]
• Invest in diagnostic-imaging renewal, digital systems, Picture Archiving and Communication Systems, radiopharmaceutical capacity, radiotherapy, hadrontherapy and biobank infrastructure, while considering maintenance costs, demand and economies of scale.[75][76][28][77]
• Plan radiotherapy renewal around reported equipment costs, including an average cost of approximately 2,000 million Euro per new linear accelerator and an estimated 370,000 million Euro for identified equipment renewal; comparable expenditure is indicated for simulators, planning systems and record-and-verify systems.[78]
• Control the costs of high-complexity robotic surgery and link tariff, reimbursement and technology decisions to appropriateness, quality and documented clinical activity.[64][48][44]
• Manage pharmaceutical sustainability through negotiated pricing, risk-sharing, cost-sharing and payment-by-results arrangements. Antineoplastic medicines represented approximately 11% of total healthcare expenditure in 2008, with 99.2% borne by the Italian National Health Service.[54][55][56]
• Mobilise targeted funding for cellular-therapy and transplantation programmes with potential clinical impact, without specifying monetary commitments.[57]
• Recognise research-investment constraints: global pharmaceutical-industry investment in Italy was reported at approximately 1% of Italian market turnover, and the programme seeks to attract greater public and private research investment.[79]

Across most prevention, care-network, training, communication, research and technology sections, the source does not provide detailed budgets, unit costs, funding-gap estimates or a comprehensive resource-mobilisation plan.[6][3][80][35][81]